AKT1 and colorectal carcinoma: Inhibitors of the PI3K/Akt signaling pathway gain considerable attention in the treatment of CRC, especially since PI3K/Akt pathway inhibition can modulate TRAIL induced apoptosis in HT29 cells [34].